Correlogic/Predicant Conflict Of Interest Would Be Prevented Under Reform
This article was originally published in The Gray Sheet
Executive Summary
Potential conflicts of interest, such as those between the National Cancer Institute, Correlogic and Predicant would have been identified and prevented under proposed NIH ethics reforms presented by Director Elias Zerhouni, NCI officials testified at a June 22 House Energy & Commerce Committee hearing
You may also be interested in...
FDA Ethics Under Spotlight Of House Oversight Subcommittee Investigation
The House Energy & Commerce/Oversight & Investigations Subcommittee is shifting its ongoing ethics investigation toward FDA, Rep. Joe Barton (R-Texas) said May 18 at an NIH ethics hearing
Correlogic Proteome Quest Ovarian Cancer Assay Propels Funding Call On Hill
Sponsors of a House resolution seeking accelerated research and health insurance coverage for a specific type of ovarian cancer test will try to include language from the legislation in the HHS appropriations conference report for fiscal 2003
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”